Skip to Content

Sonidegib use while Breastfeeding

Drugs containing Sonidegib: Odomzo

Medically reviewed by Drugs.com. Last updated on Dec 7, 2020.

Sonidegib Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of sonidegib during breastfeeding. Because sonidegib is 97% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 28 days and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during sonidegib therapy.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Sonidegib

CAS Registry Number

956697-53-3

Drug Class

  • Breast Feeding
  • Lactation
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Hedgehog Pathway Inhibitors
  • Signal Transduction Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.